Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19

NCT04402866 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT04402866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19
Lead sponsor
Theravance Biopharma
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2020
Completion date
April 21, 2021
Enrollment
235 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury (ali) associated with covid-19, lung inflammation associated with covid-19